How Different Psilocybin Doses Shape the Brain and Behavior
New research exploring the effects of psilocybin, the active compound found in magic mushrooms, is shedding light on an important question in psychedelic science: how does dosage influence the brain and its therapeutic potential?
As anyone who has used magic mushrooms knows — dose is everything. It’s the difference between gentle tingles and being catapulted head-first into the psychedelic cosmos, the difference between feeling vibey and feeling, well, epic. But when it comes to more formalised, therapeutic uses, what’s the deal?
Well, a study published in the Journal of Psychopharmacology may be pointing towards an answer. The study examined how varying doses of psilocybin affect behavior and neural activity in mice. The findings suggest that moderate doses may reduce anxiety-like behaviors, while higher doses appear to produce antidepressant-like effects and stimulate markers linked to new neural connections. Basically, different doses might be better at treating different needs.
While the research was conducted in animals, it provides valuable clues about how different levels of psychedelic activity in the brain may eventually inform more precise treatments for mental health conditions in humans. So let’s dive in!
Psilocybin and the Brain
Psilocybin occurs naturally in several species of psychedelic mushrooms. After ingestion, the body converts psilocybin into psilocin, a compound that interacts with serotonin receptors in the brain (particularly the 5-HT2A-reseptori) which plays a major role in perception, mood, and cognition.
In recent years, clinical trials have shown that psilocybin therapy can produce rapid and long-lasting relief from major depressive disorder, sometimes after only one or two sessions.
Yet one scientific mystery remains: how can a substance that leaves the body within hours produce benefits that last weeks or even months?
“Psilocybin has shown remarkably rapid and long-lasting antidepressant effects in clinical trials, but we still don’t fully understand how a drug that leaves the body within hours can produce therapeutic benefits that last for weeks or even months,” explained study author Connor Maltby, the head of Translational Medicine at Ulysses Neuroscience Ltd.
“One major hypothesis is that psychedelics work by enhancing neuroplasticity, but the relationship between receptor activation, behavioral effects, and downstream biological changes hasn’t been clearly mapped out. We wanted to understand how the degree of engagement of the brain’s primary psychedelic target (the 5-HT 2A ) receptor relates to both behavioral outcomes and molecular markers of plasticity in specific brain regions.”
“This kind of mechanistic understanding is critical if we want to move beyond empirical dosing toward rational development of psychedelic-inspired treatments for neuropsychiatric disorders. In other words, we’re trying to move the field from ‘psychedelics work’ to ‘how much receptor activation is needed to produce which kind of therapeutic effect?’”
Measuring Psilocybin’s Effects in the Brain
To explore these questions, researchers conducted a series of experiments using male mice. The goal was to track how different doses influenced both receptor activity in the brain and observable behavior.
Six groups of mice were given injections of psilocybin at doses ranging from 0.1 to 10 milligrams per kilogram of body weight, while another group received a placebo.
Thirty minutes after dosing, scientists measured receptor occupancy in the prefrontal cortex. This term describes the proportion of serotonin receptors that are actively bound by a drug at a given moment.
A specialized radioactive tracer allowed the team to calculate how many receptors were engaged by psilocybin at each dose level.
Tracking Psychedelic Activity Through the “Head Twitch” Response
Researchers then examined a well-known behavioral marker used in psychedelic studies with rodents: the pään nykimisreaktio.
This rapid head movement is considered a reliable indicator that a compound is producing hallucinogenic-like effects in animals.
Groups of 12 mice were placed in observation chambers equipped with high-speed cameras. Artificial-intelligence tracking software counted the number of head twitches occurring over a 20-minute period.
The results revealed a curved relationship between dose and response.
The largest total number of head twitches occurred at a moderate dose of 1 milligram per kilogram. However, the fastest rate of head twitching per minute appeared at a higher dose of 3.2 milligrams per kilogram, corresponding to about 62 percent receptor occupancy.
At the highest doses, researchers also noticed that the mice tended to move less overall.
Testing Anxiety-Like Behavior
To investigate how psilocybin might affect anxiety, scientists used a common behavioral test known as the elevated plus maze.
This apparatus features open and enclosed pathways raised above the ground. Because mice naturally prefer enclosed areas, spending more time in open spaces indicates reduced anxiety-like behavior.
Groups of mice were given different doses of psilocybin before entering the maze.
The moderate dose of 1.5 milligrams per kilogram increased the amount of time mice spent exploring the open sections. higher dose of 3 milligrams per kilogram did not produce the same effect, suggesting that anxiety-related responses may be dose-dependent.
Signs of Antidepressant-Like Effects
After the maze experiment, researchers waited four hours before conducting another test often used in mood research: the forced swim test.
In this test, mice are placed in small cylinders of water for six minutes while researchers measure how long they remain actively swimming compared with floating passively.
The higher dose of psilocybin reduced the amount of time the mice spent floating, which is interpreted as an antidepressant-like effect. The moderate dose did not show this change.
“While this was a preclinical study in mice, one encouraging finding was that the levels of 5-HT 2A receptor engagement associated with behavioral and plasticity-related effects in our experiments were broadly consistent with those linked to subjective and therapeutic effects in human imaging studies,” Maltby told PsyPost.
“That kind of cross-species alignment suggests that receptor occupancy may eventually serve as a useful biological framework for understanding and potentially optimising dosing in clinical settings. Rather than relying solely on subjective experience, future treatments might be guided by measurable engagement of specific neural targets.”
Psilocybin and Neuroplasticity
Beyond behavior, the scientists examined how psilocybin affected neuroplastisuus, aka the brain’s ability to reorganize itself by forming new neural connections.
They analyzed structures called microtubules, which help neurons maintain their shape and grow new branches. They also measured proteins associated with synapses, the junctions where brain cells communicate.
Both moderate and high doses altered the chemical structure of microtubules, making them more dynamic and capable of remodeling. These changes appeared in two key brain regions:
- The prefrontal cortex, involved in complex thinking and decision-making
- The amygdala, which plays a major role in emotional processing and fear responses
Interestingly, increases in synaptic proteins were observed only in the prefrontal cortex, not the amygdala.
“One interesting finding was that psilocybin increased markers of synaptic plasticity in the prefrontal cortex but not in the amygdala, even though both regions showed signs of increased microtubule dynamics,” Maltby said.
“This suggested that different brain regions may respond to psychedelic-induced receptor activation in distinct ways, potentially supporting different therapeutic outcomes such as anxiolytic versus antidepressant effects. It highlights that the brain’s response to psychedelics may be region-specific rather than globally uniform.” — Basically, the magic is in the dose.
Rethinking the Role of Dose
One takeaway from the research is that more intense psychedelic effects do not necessarily produce the same biological outcomes.
Moderate doses in this study appeared more closely tied to reduced anxiety-like behavior, kun taas higher doses were associated with antidepressant-like responses and stronger neuroplastic changes.
“One common misconception is that the intensity of the psychedelic experience is necessarily tied to therapeutic benefit,” Maltby told PsyPost. “Our findings support a more nuanced view, that different degrees of receptor engagement may produce distinct biological and behavioral outcomes.”
Why Animal Studies Still Matter
Although mice cannot report emotions such as sadness or anxiety, animal models remain a key tool in neuroscience. Researchers rely on observable behaviors and biological measurements to study how drugs interact with the nervous system.
These experiments allow scientists to monitor receptor activity and structural brain changes in ways that are difficult to achieve in human trials.
“It’s important to note that behavioral assays in animals are best viewed as pharmacodynamic readouts rather than direct models of human depression or anxiety,” Maltby said. “They help us understand the biology involved, but translating those findings into clinical treatment still requires careful human studies.”
The Next Phase of Psychedelic Research
The research team plans to continue investigating psilocybin using animal models exposed to chronic stress or inflammation, conditions that more closely resemble the biological features of human depression.
“Ultimately, the goal is to understand whether specific levels of receptor activation can be linked to particular therapeutic outcomes, which could inform the development of next-generation psychedelic or psychedelic-derived compounds with improved safety and precision, as well as reduced psychoactivity (hallucinations),” Maltby added.
“…we hope this study contributes to a more mechanistic understanding of how these compounds work—which will be essential for translating early clinical promise into scalable treatments for neuropsychiatric disorders.”
The study, “An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice,” was authored by Connor J. Maltby, Adam K. Klein, Enya Paschen, Jessica Pinto, Dino Dvorak, Joseph R. Hedde, Ashley N. Hanks, Massimiliano Bianchi, and Zoë A. Hughes.
